Chimeric papillomavirus virus-like particles induce a murine self- antigen-specific protective and therapeutic antitumor immune response

Journal of Cellular Biochemistry

Volumn 73, Issue 2, 1999, Pages 145-152

  Nieland, John D ^a   Da Silva, Diane M ^a,b   Velders, Markwin P ^a   De Visser, Karin E ^a   Schiller, John T ^c   Müller, Martin ^b   Kast, W Martin ^a,b  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Chimeric virus like particles; Immunotherapy; P1A; P815; Peptide induced tolerance

Indexed keywords

TUMOR ANTIGEN;

ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNOTHERAPY; CHIMERA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GROWTH INHIBITION; IMMUNE RESPONSE; IMMUNIZATION; MALE; MOUSE; NONHUMAN; PAPILLOMA VIRUS; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH;

ANIMALS; BASE SEQUENCE; CHIMERA; DNA PRIMERS; IMMUNOTHERAPY; MALE; MICE; MICE, INBRED DBA; NEOPLASMS, EXPERIMENTAL; PAPILLOMAVIRIDAE; T-LYMPHOCYTES, CYTOTOXIC; VIRION;

EID: 0033135288     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4644(19990501)73:2<145::AID-JCB1>3.0.CO;2-5     Document Type: Article

References (26)

1. Amar-Costesee A, Godelaine D, Van den Eynde B, Beaufay H. 1994. Identification and characterization of the tumor-specific P1A gene product. Biol Cell 81:195-203.
2. Armstrong TD, Pulaski BA, Ostrandrosenberg S. 1998. Tumor antigen presentation: Changing the rules. Cancer Immunol Immunother 46:70-74.
3. + cytotoxic T lymphocytes. Eur J Immunol 26:2595-2600.
4. De Bruijn ML, Greenstone HL, Vermeulen H, Melief CJM, Lowy DR, Schiller JT, and Kast WM. 1998. L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250:371-376.
5. Dupuy C, Buzoni-Gatel D, Touze A, Le Cann P, Bout D, Coursaget P. 1997. Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathogen 22:219-225.
6. Gilboa E, Nair SK, Lyerly HK. 1998. Immunotherapy of cancer with dendritic cell-based vaccines. Cancer Immunol Immunother 46:82-87.
7. Grabbe S, Beissert S, Schwarz T, Granstein RD. 1995. Dendritic cells as initiators of tumor immune responses: A possible strategy for tumor immunotherapy? Immunol Today 16:117-121.
8. Greenstone HL, Nieland JD, De Visser KE, De Bruijn ML, Kirnbauer R, Roden RBS, Lowy DR, Kast WM, Schiller JT. 1998. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc Natl Acad Sci USA 95:1800-1805.
9. Grohmann U, Bianchi R, Ayroldi E, Belladonna ML, Surace D, Fioretti, MC, Puccetti P. 1997. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL12 can prevent or revert the anergic state. J Immunol 158:3593-3602.
10. Hagensee ME, Olson NH, Baker TS, Galloway DA. 1994. Three-dimensional structure of vaccinia virus-produced human papillomavirus type 1 capsids. J Virol 68:4503-4505.
11. Kirnbauer R, Booy F, Cheng N, Lowy DR, Schiller JT. 1992. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89:12180-12184.
12. Kirnbauer R, Taub J, Greenstone H, Roden R, Durst M, Gissmann L, Lowy DR, Schiller JT. 1993. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol 67:6929-6936.
13. Lethe B, Van den Eynde B, Van Pel A, Corradin G, Boon T. 1992. Mouse tumor rejection antigens P815Aand P815B: Two epitopes carried by a single peptide. Eur J Immunol 22:2283-2288.
14. Loman R, Rueda P, Sedlik C, Deriaud E, Casal I, Leclerc C. 1998. A recombinant virus-like particle system derived from parvovirus as an efficient antigen carrier to elicit a polarized Th1 immune response without adjuvant. Eur J Immunol 28:1401-1407.
15. Müller M, Zhou J, Reed TD, Rittmuller C, Burger A, Gabelsberger J, Braspenning J, Gissmann L. 1997. Chimeric papillomavirus-like particles. Virology 234:93-111.
16. Pardoll DM. 1998. Cancer vaccines. Nature Med 4:525-531.
17. Peng S, Frazer IH, Fernando GJ, Zhou J. 1998. Papillomavirus virus-like particles can deliver defined CTL epitopes to the MHC class I pathway. Virology 240:147-157.
18. Rock KL. 1996. A new foreign policy: MHC class I molecules monitor the outside world. Immunol Today 17:131-137.
19. Schirmbeck R, Bohm W, Reimann J. 1996. Virus-like particles induce MHC class Irestricted T-cell responses. Lessons learned from the hepatitis B small surface antigen. Intervirology 39:111-119.
20. Toes REM, Offringa R, Blom RJJ, Melief CJM, Kast WM. 1996a. Peptide vaccination can lead to enhance tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci USA 93:7855-7860.
21. Toes REM, Blom RJJ, Offringa R, Kast WM, Melief CJM. 1996b. Functional deletion of tumorspecific CTL induced by peptide vaccination can lead to the inability to reject tumors. J Immunol 156:3911-3918.
22. Toes REM, Vandervoort EIH, Schoenberger SP, Drijfhout JW, Vanbloois L, Storm G, Kast WM, Offringa R, Melief CJM. 1998. Enhancement of tumor outgrowth through CTL tolerization after peptide vaccination is avoided by peptide presentation on dendritic cells. J Immunol 160: 4449-4456.
23. Van den Eynde B, Mazarguil H, Lethe B, Laval F, Gairin JE. 1994. Localization of two cytotoxic T lymphocyte epitopes and three anchoring residues on a single nonameric peptide that binds to H2Ld and is recognized by cytotoxic T lymphocytes against mouse tumor P815. Eur J Immunol 24:2740-2745.
24. Velders MP, Nieland JD, Rudolf MP, Loviscek K, Weijzen S, de Visser KE, Macedo MF, Carbone M, Kast WM. 1998. Identification of peptides for immunotherapy of cancer. It is still worth the effort. Crit Rev Immunol 18:727.
25. Velders MP, Schreiber H, Kast WM. 1998. Active immunization against cancer cells: Impediments and advances. Semin Oncol 25:110.
26. Wick M, Dubey P, Koeppen H, Siegel CT, Fields PE, Chen LP, Bluestone, JA, Schreiber H. 1997. Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy. J Exp Med 186:229-238.